Protein Hardware for Signaling

CHAPTER 25 Protein Hardware for Signaling


This chapter introduces proteins that transduce signals in the cytoplasm: protein kinases, protein phosphatases, guanosine triphosphatases (GTPases), and adapter proteins. Remarkably, kinases and GTPases use the same strategy to operate molecular switches that carry information through signaling pathways: the simple addition and removal of inorganic phosphate. Protein kinases add phosphate groups to specific protein targets, and phosphatases remove them. GTPases bind guanosine triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP) and inorganic phosphate, which dissociates. In both cases, the presence or absence of a single phosphate group switches a protein between active and inactive conformations.


Because addition of phosphate is reversible, both types of switches can be used as molecular timers that cycle on and off at tempos determined by the intrinsic properties of the switch and its environment. GTPases are active with bound GTP and switch off when they hydrolyze GTP to GDP. Similarly, phosphorylation activates many proteins but can inhibit others. In all of these examples, a single protein acts as a simple binary switch.


These molecular switches are often linked in series to form a signaling cascade that can both transmit and refine signals. Enzymes along signaling pathways (including kinases) often act as amplifiers. Turning on the binary switch of one enzyme molecule can produce many product molecules, each of which, in turn, may continue to propagate and amplify the original signal by activating downstream molecules. Other pathways involve negative feedback loops. Few signaling pathways are linear; instead, most branch and intersect, allowing cells to integrate information from multiple receptors and to control multiple effector systems simultaneously. Chapter 27 illustrates the functions of molecular switches in several signaling pathways.



Protein Phosphorylation


Phosphorylation is the most common posttranslational modification of proteins and regulates the activity of one or more proteins along most signaling pathways. Among other things, phosphorylation controls metabolic enzymes, cell motility, membrane channels, assembly of the nucleus, and cell cycle progression. Sometimes, phosphorylation turns a process on; sometimes, it turns one off. In either case, both the addition of a phosphate by a protein kinase and its removal by a protein phosphatase are required to achieve regulation.


For historical and practical reasons, it has been easier to study protein kinases than protein phosphatases, so most research and accounts of regulation by phosphorylation emphasize kinases (witness the 361,167 PubMed hits for “protein kinase” compared with 127,267 for “protein phosphatase” in August 2006). Furthermore, many researchers assumed incorrectly that phosphatases are always active, leading to a lack of interest in their roles in signaling reactions. Readers should not forget that both directions are important on this two-way street.


In eukaryotes, more than 99% of protein phosphorylation occurs on serine and threonine residues, but phosphorylation of tyrosine residues regulates many processes in animals (Fig. 25-1). Bacteria and Archaea use histidine and aspartate phosphorylation for signaling (see Fig. 27-11), but these modifications are little known in eukaryotes. Phosphohistidine and phosphoaspartate are more difficult to assay than are other phosphorylated residues, so pathways using these phosphoamino acids might have escaped detection.


image

Figure 25-1 structures of phosphoamino acids. In addition to the N1 nitrogen illustrated, histidine is often phosphorylated on N3 at the upper left.



Effects of Phosphorylation on Protein Structure and Function


Despite its small size, phosphate is well suited to cause changes in the activity of proteins. The addition of a phosphate group with two negative charges to a single amino acid can change the conformation of a protein or alter interactions with other molecules, including the interaction of substrates with enzymes. A phosphate group can alter the activity of a protein in sever-al ways:


• Direct interference. A phosphate group can directly block the binding site for a ligand. For example, phosphorylation inhibits the metabolic enzyme isocitrate dehydrogenase by blocking substrate binding to the active site (Fig. 25-2). Both direct steric hindrance and electrostatic repulsion between the negatively charged phosphate and negatively charged substrates prevent substrate binding. Phosphorylation also can directly block protein assembly reactions, such as the polymerization of intermediate filaments (see Fig. 35-4) and binding of ADF/cofilin proteins to actin monomers and filaments (see Fig. 44-6).

• Conformational change. A phosphate group can participate in hydrogen bonds and electrostatic interactions distinct from those of the hydroxyl group that it replaces on an amino acid side chain. In many cases, these interactions of phosphorylated residues change the conformation of the protein. For example, phosphorylation activates the insulin receptor tyrosine kinases by inducing a dramatic change in a polypeptide loop on its surface (Fig. 25-3E). In the inactive conformation, this loop blocks the substrate-binding site and slows down the phosphorylation reaction. Phosphorylation of a single serine activates the metabolic enzyme glycogen phosphorylase by stabilizing a compact, active conformation.

• Creation of binding sites. Reversible phosphorylation controls interactions between partner proteins that require a phosphorylated residue to complete a binding site (Fig. 25-10A). Phosphorylated tyrosines are required for SH2 (Src homology) domains and phosphotyrosine-binding (PTB) do-mains to recognize their protein ligands. A phosphoserine is required on protein ligands for binding 14-3-3 domains, some WW domains, and some FHA domains.

image

Figure 25-2 phosphorylation blocks substrate binding to isocitrate dehydrogenase. A, Surface representation with isocitrate (blue) bound to the active site. B, Phosphorylation of serine 113 (yellow) blocks isocitrate binding. (PDB files: 3ICD and 4ICD.)


image

Figure 25-3 protein kinase structures. A, Ribbon diagram and space-filling model of cAMP-dependent protein kinase with a nonhydrolyzable ATP analog (red) bound to the active site. The adenine base of the ATP fits into a hydrophobic cleft formed by b-sheets lining the interface of the two lobes. The phosphates bind to conserved residues in loops connecting the b-strands. (PDB file: 1CPK.) B, Space-filling model of PKA with bound inhibitory peptide PKI. The location of this inhibitory peptide revealed the binding site for protein substrates. (PDB file: 1FMO.) C, Ribbon diagram of c-Src. When tyrosine-527 is phosphorylated, the SH2 domain binds intramolecularly to the C-terminus, locking the kinase in an inactive conformation. The N-terminal SH3 domain binds intramolecularly to a proline-rich sequence (PPII helix) connecting the SH2 and kinase domains. NT and CT are the N- and C-terminal lobes of the kinase domain. D, Ribbon diagram of PKA bound to the RIa regulatory subunit. The pseudo substrate peptide (yellow) sits in the active site. Binding of cAMP to two sites on the RIa subunit causes a conformational change that dissociates RIa from the catalytic subunit. (PDB file: 1U7E.) E, Insulin receptor tyrosine kinase. Ribbon diagram and space-filling model with the catalytic loop in orange and the activation loop in green. (PDB file: 1IRK.) F, Space-filling model of insulin receptor tyrosine kinase triphosphorylated on the activation loop. This rearranges the activation loop, allowing substrates (pink with a white tyrosine side chain) access to the active site. AMP-PNP is a nonhydrolyzable analog of ATP with nitrogen bridging the b- and γ-phosphates. (PDB file: 1IR3.)


(E–F, Space-filling models courtesy of Steven Hubbard, New York University, New York.)


image

Figure 25-10 atomic models of adapter protein domains. Ribbon diagrams show their architecture, and the surface renderings show how ligands bind. A, Domains with phosphorylation-sensitive interactions. B, Domains with poly-l-proline ligands. C, Domains with other ligands. SH2 (PDB file: 1HCS), PTB (PDB file: 1IRS), PH (PDB file: 1DYN), 14-3-3 (PDB file: 1A38); SH3 (PDB file: 1ABO) and EVH1 (PDB file: 1EVH); PDZ (PDB file: 1BEQ) and EH (PDB file: 1EH2).



Protein Kinases


Protein kinases catalyze the transfer of the g-phosphate from adenosine triphosphate (or, rarely, guanosine triphosphate) to amino acid side chains of proteins. Protein kinases are important, as is evident from the remarkable number of genes: 116 in budding yeast (second only to transcription factor genes), 409 in nematode worms (second only to seven-helix receptor genes), and 518 in humans. Most protein kinases in eukaryotes are either serine/threonine kinases or tyrosine kinases (Appendix 25-1). The difference is that most serine/threonine kinases phosphorylate either serine and threonine but not tyrosine, while most tyrosine kinases phosphorylate tyrosine but not serine or threonine.


Most serine/threonine and tyrosine kinases had a common evolutionary origin and share similar structures and catalytic mechanisms, despite differences in substrate specificity. Tyrosine kinases emerged in animals after their divergence from fungi. Nevertheless, fungi have phosphotyrosine owing to two families of serine/threonine kinases that also phosphorylate tyrosine and three protein tyrosine phosphatases to reverse these reactions. A family of 40 “atypical” protein kinases had a separate origin from the major family. Lipid kinases have a catalytic domain related to typical protein kinases. They phosphorylate inositol phospholipids (see Fig. 26-7) or a few proteins.


The catalytic domain of eukaryotic protein kinases consists of about 260 residues in two lobes surrounding the ATP-binding pocket (Fig. 25-3). Despite extensive sequence divergence, all of these kinases have a similar polypeptide fold with conserved residues at critical positions required for catalysis.


Each kinase has a restricted range of protein substrates, so activation of a particular protein kinase changes the phosphorylation and activity of a discrete set of target proteins. Substrate specificity is achieved by selective binding of substrates to a groove on the surface of the kinase (Fig. 25-3B). This groove recognizes amino acids that flank the phosphorylatable residue and position the acceptor amino acid side chain in the active site. Typically, all substrates that bind a particular kinase have similar residues surrounding the target serine, threonine, or tyrosine (a consensus target sequence). For example, the consensus sequence for protein kinase A (PKA) is Arg-Arg-Gly-Ser/Thr-Ile. The arginines and isoleucine flanking the target serine or threonine residue specify binding to PKA. Interactions outside the catalytic site may also contribute to specific binding.


In addition to the catalytic domain, most protein kinases have other domains for regulation or localization (Fig. 25-4). Adapter domains, such as SH2, SH3, and pleckstrin homology domains (Fig. 25-11), target kinases to specific sites in the cell. Such localization can either bring together a kinase and its substrates or limit their interaction. Transmembrane segments anchor receptor kinases to membranes. Receptor tyrosine kinases usually have additional residues inserted in the kinase domain and at the C-terminus. Phosphorylation of tyrosines in these inserts creates binding sites for effector proteins with SH2 domains (see Figs. 27-6, 27-7, and 27-8).


image

Figure 25-4 protein kinase domain architecture. See Appendix 25-1 for definitions of the kinase names. Btk, Bruton tyrosine kinase; Ca, calcium-binding site; cAMP and cGMP, cyclic nucleotide–binding sites; CM, overlapping pseudosubstrate/calmodulin-binding site; DAG, diacylglycerol-binding site; FGFR, fibroblast growth factor receptor; Ig, immunoglobulin domains; PH, pleckstrin homology domain; PS, pseudosubstrate sequences; SH2 and SH3, Src-homology domains; TM, transmembrane domain.


image

Figure 25-11 scale drawings of proteins with adapter domains. c-Crk and Grb2, multidomain adapter proteins; DBL, a guanine nucleotide exchange factor domain; GAP, GTPase activating; IRS1, insulin receptor substrate; PH, pleckstrin homology; PLC, phospholipase C; poly-P, polyproline; PTB, protein tyrosine–binding domain; PTPLC, protein tyrosine phosphatase; Ras-GAP, Ras GTPase activating protein; SH, Src-homology; Src, cytoplasmic tyrosine kinase; Vav, a guanine nucleotide exchange protein; WASp, Wiskott-Aldrich syndrome protein. Actin and Arp2/3 indicate binding sites for actin monomers and Arp2/3 complex. Cdc42, a Rho-family GTPase; EVH1, Ena-Vasp homology 1 domain.


Prokaryotes generally lack serine/threonine/tyrosine kinases but use a large family of histidine kinases for signal transduction (see Fig. 27-11). These prokaryotic kinases differ in structure, mechanism and evolution-ary origin from eukaryotic kinases. A few bacteria have acquired eukaryotic kinases by lateral transfer of genes.



Regulation of Protein Kinases


Each kinase has its own regulatory mechanism, but most involve one or more of three strategies: (1) phosphorylation, (2) interactions with intrinsic peptides or extrinsic subunits that may themselves be targets for second messengers or regulatory proteins, and (3) targeting to specific cellular locations, such as the nucleus, plasma membrane, or cytoskeleton, enhancing interaction with specific substrates.



Phosphorylation


Phosphorylation can either activate or inhibit protein kinases. In some cases, another kinase molecule of the same type carries out the phosphorylation, but often another type of kinase is responsible. When linked in series, different types of kinases form signaling cascades that can amplify and sharpen the response to a stimulus (see Fig. 27-5):


• Activation by phosphorylation. This is the most common way to regulate kinases. For example, phosphorylation of three tyrosines on an activation loop activates the insulin receptor kinase. Phosphorylation refolds the activation loop, allowing substrates access to the active site and bring-ing together the residues required for catalysis (Fig. 25-3D). Activation loop phosphorylation also turns on other receptor tyrosine kinases, Src-family tyrosine kinases (Fig. 25-3C; see also Box 27-1), mitogen-activated protein (MAP) kinases (see Fig. 27-5), cyclin-dependent kinases (see Fig. 40-14), and calcium-calmodulin–dependent kinases (Fig. 25-4).

• Inhibition by phosphorylation. Phosphorylation of myosin light-chain kinase by protein kinase A reduces its affinity for its protein substrate, and phosphorylation of platelet-derived growth factor receptor tyrosine kinase by protein kinase C inhibits its activity. Phosphorylation of a C-terminal tyrosine inhibits Src-family tyrosine kinases by creating an intramolecular binding site for an SH2 domain at the N-terminus (Fig. 25-3C). This interaction traps the kinase in an inactive conformation. Phosphorylation of certain residues also inhibits cyclin-dependent cell cycle kinases (see Fig. 40-14).


Regulation of Substrate Binding


Peptides that are intrinsic to the kinase or part of a separate protein can inhibit kinases by competing with protein substrates for binding to the enzyme (Figs. 25-3B and D and 25-4):


• Extrinsic regulation by inhibitory subunits. Separate regulatory (R) subunits inhibit PKA by blocking the protein substrate site with a pseudosubstrate (Figs. 25-3D and 25-4). Pseudosubstrates have consensus target sequences lacking the phosphorylated residue. For example, RI pseudosubstrate has the sequence Arg-Arg-Gly-Ala-Ile, which binds in the substrate groove but is not phosphorylated, as it has alanine or glycine, rather than serine, at the phosphorylation site. The RII pseudosubstrate has a serine, which is phosphorylated but then does not dissociate from the catalytic subunit as phosphorylated substrates do. Cyclic adenosine monophosphate (cAMP) regulates the affinity of these regulatory subunits for the catalytic subunit. In resting cells, the regulatory subunit is free of cAMP and binds the catalytic subunit with high affinity. With a rise in cAMP concentration (see Fig. 26-3), cAMP binds the regulatory subunit, dissociates it from the catalytic subunit, and allows substrates access to the active site.

• Autoinhibition. Many kinases have an intrinsic pseudosubstrate sequence (see Fig. 25-4) that binds intramolecularly to the active site, autoinhibiting the enzyme (Fig. 25-3B). Ca2+-calmodulin activates myosin light-chain kinase and calmodulin-activated kinase (CaMK) by binding immediately adjacent to the pseudosubstrate and displacing the inhibitory peptide from the kinase. Cyclic guanosine monophosphate (cGMP) binding to protein kinase G (PKG) displaces the autoinhibitory peptide from the catalytic domain, activating the enzyme.

• Extrinsic regulation by activating subunits. Regulatory subunits can also activate protein kinases. Regulatory subunits called cyclins bind and contribute to activating cyclin-dependent cell cycle kinases, Cdks (see Fig. 40-14).

• Dual or triple regulation. Multiple factors regulate most kinases. Both interaction of calcium-calmodulin with an intrinsic pseudosubstrate and activation loop phosphorylation activate CaMK. Both inhibitory and activating phosphorylation, as well as cyclins and inhibitory subunits, regulate cyclin-dependent kinases.


Targeting


Several mechanisms target kinases to specific cellular locations, bringing them close to particular substrates. This targeting helps to explain how kinases with broad specificity can have specific effects in particular target cells:


• The intracellular location of PKA is determined by both its RI and RII subunits and a family of A kinase–anchoring proteins (AKAPs). When the cAMP concentration is low, regulatory subunits bind and inhibit PKA. RII subunits also bind to AKAPs, which can target the inhibited PKA catalytic subunit to different cellular locations, including centrosomes, actin filaments, microtubules, endoplasmic reticulum, peroxisomes, mitochondria, or plasma membrane. An increase in cytoplasmic cAMP releases active PKA in close proximity to particular substrates. Once freed from RI or RII subunits by cAMP, the active PKA catalytic subunit can migrate into the nucleus, where it encounters a different array of substrates and regulates gene transcription (see Fig. 26-3F). The inhibitory protein PKI (Fig. 25-3B) is capable of capturing PKA in the nucleus, thereby targeting it for transport back to the cytoplasm. Some AKAPs bind other protein kinases, such as protein kinase C and phosphatases (PP2B). Similar to AKAPs, the inner centromere protein, INCENP, binds and targets aurora-B kinase to various structures during cell division: centromeres early in mitosis and the central spindle and cleavage furrow late in mitosis (see Chapter 44).

• Pleckstrin homology (PH) domains (Fig. 25-10A) and lipid tags target some kinases to lipid bilayers. A PH domain directs PKB/Akt to membrane polyphosphoinositides. This interaction with lipids opens up sites on the catalytic domain for phosphorylation and activation by PDK1, another kinase with a pleckstrin homology domain. An N-terminal myristic acid anchors Src tyrosine kinase to the plasma membrane.

• Phosphorylation induces the MAP kinase ERK2 to form homodimers, triggering movement of the dimer into the nucleus, where it regulates gene expression.

• A scaffolding protein called STE5, first identified in yeast, brings together three protein kinases that form part of the cascade of kinases that activate MAP kinases (see Fig. 27-5).


Kinases and Disease


Unregulated kinases—for example, the receptor tyrosine kinase RET in endocrine cancers and cyclin-dependent kinase Cdk4 in melanoma—can predispose individuals to cancer. Most patients with chronic myelogenous leukemia have a gene rearrangement that produces a fusion between the protein bcr and c-abl, a nonreceptor tyrosine kinase. The constitutively active fusion protein promotes the transformation of white blood cell precursors into cancer cells. The most effective treatment is with a small molecule called imatinib mesylate (Gleevec), which inhibits bcr-abl kinase activity and kills myelogenous leukemia cells. Inactivation of the serine/threonine kinase LKB1 causes Peutz-Jeghers syndrome with predisposition to various cancers.



Protein Phosphatases


Eukaryotes have several families of protein phosphatases that remove phosphate from amino acid side chains (Table 25-1 and Fig. 25-5). Like protein kinases, most protein phosphatases are active toward either phosphoserine/threonine or phosphotyrosine, although several dual-specificity phosphatases can dephosphorylate all three residues. The 90 active protein tyrosine phosphatases far outnumber the 20 serine/threonine phosphatase genes in the human genome. Each tyrosine phosphatase is thought to act on a limited number of substrates. The small number of serine/threonine phosphatases achieve specificity by associating with an array of accessory subunits, which regulate enzyme activity and target catalytic subunits to particular substrates. Domains flanking the catalytic domains also regulate enzyme activity (Fig. 25-6).



Table 25-1 PROTEIN PHOSPHATASES

image

image

Figure 25-5 protein phosphatase structures (red asterisks mark the active sites). A, Serine/threonine phosphatases: PP1a1 (PDB file: 1FJM) and PP2C (PDB file: 1A6O). B, Four families of protein tyrosine phosphatases: receptor tyrosine phosphatase RPTPa (PDB file: 1YFO), dual-specificity phosphatase VHR (PDB file: 1VHR), Cdc25A (PDB file: 1C25), and low-molecular-weight phosphatase (PDB file: 1PNT).


image

Figure 25-6 protein phosphatase domain architecture. scale linear models. A, Serine/threonine phosphatases. B, Protein tyrosine phosphatases. The five different catalytic domain folds are coded with different colors. CB, calcium binding; CM, calmodulin-binding; TM, transmembrane segment.



PPP Family of Serine/Threonine Phosphates


Members of the PPP family of serine/threonine phosphatases are found in Bacteria, Archaea, and all tissues of eukaryotes. PP1 and PP2A are two of the most evolutionarily conserved enzymes. All three PPP subfamilies share the same catalytic fold with a two-metal ion cluster (Fe2+ and Zn2+ in vivo) in the active site (Fig. 25-5A). Diverse regulatory subunits restrict the substrates for PP1 and PP2A by targeting catalytic subunits to specific sites in the cell, as illustrated by the following examples:


• PP1: More than 50 associated proteins target a 38-kD catalytic subunit of PP1 to specific substrates. For example, M subunits target PP1 to myosin-II, where dephosphorylation of regulatory light chains relaxes smooth muscle (see Fig. 39-21). The complex of PP1 with an M subunit creates an active site that is specific for myosin-II light chains relative to other substrates. G subunits regulate glucose metabolism by targeting PP1 to glycogen particles, where it dephosphorylates two enzymes that control glycogen metabolism. Dephosphorylation inactivates glycogen phosphorylase, turning off glycogen breakdown, and activates glycogen synthase. The hormone adrenaline stimulates cells to mobilize energy stores by breaking down glycogen (see Fig. 27-3

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Chromosome Organization
  2. Second Messengers
  3. Endocytosis and the Endosomal Membrane System
  4. Biophysical Principles

Stay updated, free articles. Join our Telegram channel
Tags:
Jun 18, 2016 | Posted by in BIOCHEMISTRY | Comments Off on Protein Hardware for Signaling

Full access? Get Clinical Tree
Get Clinical Tree app for offline access